Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Rx Enforcement Letter Output Drops In 2011; OPDP Sees Improvement In Promotions

Executive Summary

The 30 letters issued are the lowest since 2008, but FDA says the number is only part of its enforcement strategy.


Related Content

Off-Label Use Discussions Should Stay Off-line, FDA Draft Guidance Says
DTC Pre-Review Guidance In The Works For Rx TV Ads, FDA’s Abrams Says
CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Drug Advertising Oversight Gets A Promotion From A Division To An Office
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts